Amphastar Pharmaceuticals has implemented aggressive corporate strategies to maximize margins and increase sales, resulting in impressive EBIT and revenue growth.

Source: https://seekingalpha.com/article/4640072-amphastar-pharmaceuticals-great-growth-at-a-high-price?source=feed_all_articles

Amphastar Pharmaceuticals, Inc. has a 12-month low of $26.76 and a 12-month high of $67.66.

Source: https://www.etfdailynews.com/2023/08/13/amphastar-pharmaceuticals-inc-nasdaqamph-shares-sold-by-oregon-public-employees-retirement-fund/

Amphastar Pharmaceuticals () last posted its quarterly earnings data on Tuesday, August 8th.

Source: https://www.americanbankingnews.com/2023/08/30/california-state-teachers-retirement-system-cuts-stock-position-in-amphastar-pharmaceuticals-inc-nasdaqamph.html

Granite Investment Partners LLC bought a new position in Amphastar Pharmaceuticals in the first quarter valued at $20,131,000.

Source: https://www.etfdailynews.com/2023/10/03/amphastar-pharmaceuticals-nasdaqamph-downgraded-to-hold-at-stocknews-com/